Md Yusof MY - Search Results

1

Md Yusof MY, Vital EM, Emery P, Savic S. Md Yusof MY, et al. Arthritis Rheumatol. 2020 Jul;72(7):1231-1233. doi: 10.1002/art.41244. Epub 2020 May 28. Arthritis Rheumatol. 2020. PMID: 32133788 Free article. No abstract available.

2

Targeting interleukin-6 in rheumatoid arthritis.

Md Yusof MY, Emery P. Md Yusof MY, et al. Drugs. 2013 Mar;73(4):341-56. doi: 10.1007/s40265-013-0018-2. Drugs. 2013. PMID: 23456676 Free article. Review.

3

B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress.

Md Yusof MY, Vital EM, Emery P. Md Yusof MY, et al. Expert Rev Clin Immunol. 2013 Aug;9(8):761-72. doi: 10.1586/1744666X.2013.816479. Expert Rev Clin Immunol. 2013. PMID: 23971754 Free article. Review.

4

Response to: 'Which B-cell subset should we target in lupus?' by Ferraccioli and Houssiau.

Arumugakani G, Vital EM, Md Yusof MY, McGonagle DG, Emery P. Arumugakani G, et al. Among authors: md yusof my. Ann Rheum Dis. 2014 Apr;73(4):e20. doi: 10.1136/annrheumdis-2013-205096. Epub 2014 Jan 15. Ann Rheum Dis. 2014. PMID: 24431390 No abstract available.

5

Certolizumab pegol in rheumatoid arthritis: current update.

Fechtenbaum M, Md Yusof MY, Emery P. Fechtenbaum M, et al. Among authors: md yusof my. Expert Opin Biol Ther. 2014 Jun;14(6):841-50. doi: 10.1517/14712598.2014.900043. Epub 2014 Mar 22. Expert Opin Biol Ther. 2014. PMID: 24654999 Review.

6

Choosing the right rituximab dose for the right patient: comment on the article by Bredemeier et al.

Vital EM, Md Yusof MY, Emery P. Vital EM, et al. Among authors: md yusof my. Arthritis Care Res (Hoboken). 2014 Oct;66(10):1591-3. doi: 10.1002/acr.22379. Arthritis Care Res (Hoboken). 2014. PMID: 24905770 Free article. No abstract available.

7

Biologics in systemic lupus erythematosus: current options and future perspectives.

Md Yusof MY, Vital EM, Emery P. Md Yusof MY, et al. Br J Hosp Med (Lond). 2014 Aug;75(8):440, 442-7. doi: 10.12968/hmed.2014.75.8.440. Br J Hosp Med (Lond). 2014. PMID: 25111095 Review.

8

Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.

Vital EM, Wittmann M, Edward S, Md Yusof MY, MacIver H, Pease CT, Goodfield M, Emery P. Vital EM, et al. Among authors: md yusof my. Arthritis Rheumatol. 2015 Jun;67(6):1586-91. doi: 10.1002/art.39085. Arthritis Rheumatol. 2015. PMID: 25707733 Free article.

9

Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.

Md Yusof MY, Vital EM, Das S, Dass S, Arumugakani G, Savic S, Rawstron AC, Emery P. Md Yusof MY, et al. Ann Rheum Dis. 2015 Sep;74(9):1734-8. doi: 10.1136/annrheumdis-2014-206496. Epub 2015 Apr 8. Ann Rheum Dis. 2015. PMID: 25854586 Free article.

10

B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.

Md Yusof MY, Vital EM, Buch MH. Md Yusof MY, et al. Curr Rheumatol Rep. 2015 Oct;17(10):65. doi: 10.1007/s11926-015-0539-7. Curr Rheumatol Rep. 2015. PMID: 26290110 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters